Dr. Orit Markowitz
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Drexel University College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 743
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Drexel University College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 240489
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
- New York-Presbyterian Hospital New York, NY
Medical groups
- Markowitz Medical PLLC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 743
- Services billed
- 6,685
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,386 | 519 |
| Destruction of precancer skin growth, 2-14 growths | 987 | 202 |
| Biopsy of related skin growth, first growth | 586 | 353 |
| Destruction of precancer skin growth, 1 growth | 462 | 298 |
| Injection of drug or substance under skin or into muscle | 374 | 32 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 374 | 32 |
| Biopsy of related skin growth, each additional growth | 348 | 156 |
| New patient office or other outpatient visit, 45-59 minutes | 124 | 124 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 94 | 64 |
| Application of light with debridement to destroy precancer skin growth | 93 | 63 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mometasone Furoate Other prescribers in New York, NY | 128 |
| Mupirocin Other prescribers in New York, NY | 127 |
| Ketoconazole Other prescribers in New York, NY | 120 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 91 |
| Hydrocortisone Other prescribers in New York, NY | 48 |
| Valacyclovir (valacyclovir hcl) Other prescribers in New York, NY | 44 |
| Minocycline Hcl Other prescribers in New York, NY | 35 |
| Econazole Nitrate | 33 |
| Finasteride Other prescribers in New York, NY | 32 |
| Minoxidil Other prescribers in New York, NY | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 49 payments worth $29,859 in total to this clinician.
| Consulting Fee | $27,259 |
|---|---|
| Food and Beverage | $1,555 |
| Compensation for services other than consulting (speaking, faculty) | $750 |
| Travel and Lodging | $295 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. Aug 2, 2025 | Consulting Fee LEVULAN KERASTICK · Dermatology | $10,000 |
| Galderma Laboratories, L.P. Jul 10, 2025 | Consulting Fee | $4,800 |
| Galderma Laboratories, L.P. Jul 10, 2025 | Consulting Fee | $4,800 |
| Galderma Laboratories, L.P. May 15, 2025 | Consulting Fee | $3,830 |
| Galderma Laboratories, L.P. May 15, 2025 | Consulting Fee | $3,830 |
| Genzyme Corporation Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Regeneron Pharmaceuticals, Inc. Nov 19, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to TARRYTOWN, NY · in-kind | $148 |
| Regeneron Pharmaceuticals, Inc. Nov 19, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to TARRYTOWN, NY · in-kind | $148 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 9 companies. The companies reported $892,417 in research payments for these studies, mostly to the institutions running them.
- Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Regeneron Pharmaceuticals, Inc. · Completed · NCT05590585 - Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)
Janssen Research & Development, LLC - TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - Monitoring response to therapy in atopic dermatitis patients treated with dupilumab using non-invasive reflectance confocal microscopy and optical coherence tomography
Regeneron Pharmaceuticals, Inc. - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Incyte Corporation - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348 - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Eli Lilly and Company · Completed · NCT05369403
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.